Lercanidipine Hydrochloride and Losartan Potassium Compound Preparation and Preparation Method Thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 19, 2015
app pub date -
Feb 25, 2013
filing date -
Apr 11, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A lercanidipine hydrochloride and losartan potassium compound preparation. In terms of mass percentage, said compound preparation contains 0.5-40% lercanidipine hydrochloride and 6.25-50% losartan potassium. Also provided is a compound preparation which utilizes lercanidipine hydrochloride and losartan potassium as the main ingredient, lactose monohydrate, microcrystalline cellulose, A-type sodium starch glycolate, povidone K30, magnesium stearate, pregelatinized starch and colloidal silicon dioxide as excipients, and opadry white as a coating in the preparation of a tablet. Clinical tests show that compared with single-component preparations, said compound preparation markedly increases the effectiveness of treatment of light and moderate hypertension, markedly reduces the incidence of adverse effects, is tolerated well by patients, and has excellent clinical application prospects.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully